Literature DB >> 36148081

Telemedicine: A promising future for inflammatory bowel disease management.

Faizan Fazal1, Mohammad Ebad Ur Rehman1, Omaima Asif2, Haris Mustafa1, Usama Tanveer1, Tehseen Haider1, Abdul Rauf Khalid1, Sajeel Saeed1, Jawad Basit1.   

Abstract

Entities:  

Keywords:  Developing countries; Disease burden; Health care

Year:  2022        PMID: 36148081      PMCID: PMC9486437          DOI: 10.1016/j.amsu.2022.104684

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


× No keyword cloud information.
To the Editor, Telemedicine is a term that refers to any activity of medical nature that involves communication despite being physically distinct [1]. In other words, it is unorthodox doctor-patient consultation, taking place virtually with patients that may be thousands of miles away from the doctor. Telemedicine means the adequate and appropriate delivery and provision of healthcare across distances [2]. Inflammatory bowel disease (IBD) is characterized by gastrointestinal illnesses that are chronic or remitting inflammatory diseases. IBD is further subdivided into two subtypes: ulcerative colitis (UC) and Crohn's disease (CD) [3]. Recent epidemiological studies have shown that cases of IBD are on a rise in developing countries such as Pakistan [4]. There are numerous difficulties in the timely diagnosis, treatment adherence, financial burden, regular follow ups, awareness, and misdiagnosis of inflammatory bowel disease [5]. All these problems can be linked to ineffective infrastructure, planning and strategies to manage patients with IBD. Studies in well-developed countries such as China show that patients with IBD bear massive financial burden due to the expensive nature of quality healthcare services, and this contributes to non-adherence to treatment [6]. Maintaining regular follow ups is another issue faced by patients with inflammatory bowel disease. A study in Brazil reported a significant reduction in irregular follow-ups during the COVID-19 era, which greatly hindered disease control [7]. Another issue is the lack of awareness regarding the etiology and treatment of IBD. Studies have demonstrated a significant association between low awareness, treatment non-adherence and anxiety in patients with IBD [8]. Anxiety and depression have further increased during the COVID-19 pandemic, particularly in elderly IBD patients [9]. All the major issues that are hindering the control of IBD can be addressed with telemedicine. Telemedicine interventions have shown a positive role in improving quality of life and reducing the number of required clinical visits in patients with IBD [10]. Telemedicine greatly benefits patients who do not have access to high-quality care due to financial or geographical barriers [11]. The results of telehealth interventions have shown to improve treatment adherence, disease activity, treatment surveillance, and knowledge related to the disease itself [12]. In addition to the patients, gastroenterologists have also demonstrated satisfaction with the incorporation of telemedicine in IBD management [13,14]. Telemedicine has also shown great promise in the management of pregnant females with IBD. An e-health portal is quite feasible for managing a pregnant IBD patient's reproductive and medication concerns during preconception and pregnancy [15]. In short, telemedicine is the most cost-effective, time-saving, and patient-friendly method to promoting patient compliance. Telemedicine can adequately resolve all problems that are encountered in the diagnosis and management of IBD patients. Investment into the necessary infrastructure to make telemedicine more accessible is essential at the government level. A reduction in the cost of telemedicine devices will be conducive to the widespread adoption of telemedicine in clinical practice. Healthcare workers and patients need to be trained to operate telemedicine devices optimally. Collaboration between all stakeholders is critical to ensure a smooth transition to telemedicine-based management of IBD patients.

Ethical approval

Not applicable.

Sources of funding

None.

Author contributions

Faizan Fazal: Study conception, write-up, critical review and approval of the final version. Mohammad Ebad Ur Rehman: Study conception, write-up, critical review and approval of the final version. Omaima asif: Study conception, write-up, critical review and approval of the final version. Haris Mustafa: Study conception, write-up, critical review and approval of the final version. Usama Tanveer: Study conception, write-up, critical review and approval of the final version. Tehseen Haider: Study conception, critical review and approval of the final version. Abdul Rauf Khalid: Study conception, write-up, critical review and approval of the final version. Sajeel saeed: Study conception, write-up, critical review and approval of the final version. Jawad basit: Study conception, critical review and approval of the final version.

Registration of research studies

Name of the registry: Not applicable Unique Identifying number or registration ID: Not applicable Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable

Guarantor

Faizan Fazal. Mohammad Ebad Ur Rehman.

Consent

Not applicable.

Provenance and peer review

Not commissioned, externally peer reviewed.

Declaration of competing interest

The authors have no conflicts of interest.
  13 in total

Review 1.  Recent advances: Telemedicine.

Authors:  R Wootton
Journal:  BMJ       Date:  2001-09-08

Review 2.  Introduction to the practice of telemedicine.

Authors:  John Craig; Victor Patterson
Journal:  J Telemed Telecare       Date:  2005       Impact factor: 6.184

3.  Telehealth and mobile health interventions in adults with inflammatory bowel disease: A mixed-methods systematic review.

Authors:  Suja P Davis; Megan Suzanne Hardin Ross; Reuben Adatorwovor; Holly Wei
Journal:  Res Nurs Health       Date:  2020-12-11       Impact factor: 2.228

Review 4.  Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis.

Authors:  Gillian Watermeyer; Leolin Katsidzira; Mashiko Setshedi; Smita Devani; Wisdom Mudombi; Chris Kassianides
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-06-30

Review 5.  Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.

Authors:  Hiroshi Nakase; Motoi Uchino; Shinichiro Shinzaki; Minoru Matsuura; Katsuyoshi Matsuoka; Taku Kobayashi; Masayuki Saruta; Fumihito Hirai; Keisuke Hata; Sakiko Hiraoka; Motohiro Esaki; Ken Sugimoto; Toshimitsu Fuji; Kenji Watanabe; Shiro Nakamura; Nagamu Inoue; Toshiyuki Itoh; Makoto Naganuma; Tadakazu Hisamatsu; Mamoru Watanabe; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-04-22       Impact factor: 7.527

Review 6.  Incidence and Prevalence of Inflammatory Bowel Disease across Asia.

Authors:  Jihye Park; Jae Hee Cheon
Journal:  Yonsei Med J       Date:  2021-02       Impact factor: 2.759

7.  Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.

Authors:  Qiao Yu; Chunpeng Zhu; Shuyi Feng; Liyi Xu; Shurong Hu; Hao Chen; Hanwen Chen; Sheng Yao; Xiaoying Wang; Yan Chen
Journal:  J Med Internet Res       Date:  2021-01-05       Impact factor: 5.428

8.  Telemedicine in clinical gastroenterology practice: what do patients prefer?

Authors:  Adi Lahat; Zina Shatz
Journal:  Therap Adv Gastroenterol       Date:  2021-02-11       Impact factor: 4.409

9.  Pregnancy-Related Beliefs and Concerns of Inflammatory Bowel Disease Patients Modified After Accessing e-Health Portal.

Authors:  Reed T Sutton; Kelsey Wierstra; Jasmin Bal; Kathleen P Ismond; Levinus A Dieleman; Brendan P Halloran; Karen I Kroeker; Richard N Fedorak; Keri-Ann Berga; Vivian W Huang
Journal:  J Can Assoc Gastroenterol       Date:  2019-12-19

Review 10.  Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Ren Mao; Minhu Chen; Lanlan Pang; Hengyu Liu; Zhidong Liu; Jinyu Tan; Long-Yuan Zhou; Yun Qiu; Xiaoqing Lin; Jinshen He; Xuehua Li; Sinan Lin; Subrata Ghosh
Journal:  J Med Internet Res       Date:  2022-03-24       Impact factor: 7.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.